Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Tyrosine kinase inhibitor

DRUG CLASS:

Tyrosine kinase inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: B - Late Trials Tyrosine kinase inhibitor Sensitive : B	Tyrosine kinase inhibitor Sensitive: B - Late Trials Tyrosine kinase inhibitor Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2